4.480USD-7.25%Mkt Cap: 355.90M $P/E: —1d ago
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the…
Industry Peers
Drug Manufacturers - Specialty & Generic$65.19BUSDP/E 23.7
$22.46BUSDP/E 19.5
$20.18BUSD
$17.25BUSDP/E 26.4
$15.47BUSDP/E 179.2
$14.18BUSDP/E 29.7
$12.96BUSD
$8.93BUSDP/E 22.7
$7.80BUSD
$6.84BUSDP/E 25.1
$6.69BUSDP/E 442.8
$5.76BUSDP/E 48.8
$3.65BUSDP/E 19.0
$3.55BUSDP/E 11.3
$2.99BUSDP/E 20.9
$2.80BUSD
$2.52BUSDP/E 56.0
$2.35BUSDP/E 16.3
$2.40BUSDP/E 12.9
$2.31BUSD
$1.92BUSDP/E 19.4
$1.89BUSD
$1.86BUSDP/E 21.0
$1.71BUSD
$1.89BUSD
$1.67BUSD
$1.48BUSDP/E 17.5
$1.50BUSDP/E 124.1
$1.40BUSDP/E 14.8
$1.12BUSDP/E 35.4
$1.18BUSDP/E 17.6
$1.23BUSD
$1.06BUSDP/E Infinity
$1.02BUSD
$1.01BUSDP/E 196.9
$985.07MUSD
$918.60MUSDP/E 14.7
$873.22MUSDP/E 38.1
$875.69MUSDP/E 12.0
$819.46MUSDP/E Infinity
$668.29MUSD
$692.84MUSDP/E 161.5
$637.05MUSDP/E 6.2
$505.77MUSDP/E 14.3
$494.34MUSD
$447.41MUSD
$427.80MUSD
$396.78MUSD
$375.56MUSD
$370.76MUSD
$343.56MUSD
$357.30MUSD
$320.48MUSDP/E 43.7
$294.94MUSDP/E 15.2
$303.08MUSDP/E 9.7
$273.62MUSDP/E 49.1
$285.23MUSD
$250.29MUSDP/E 47.6
$255.34MUSDP/E 12.7
$236.39MUSDP/E 53.0
$206.95MUSDP/E 10.3
$210.49MUSD
$195.77MUSD
$185.67MUSD
$182.70MUSDP/E 8.8
$164.20MUSD
$143.26MUSDP/E 18.3
$146.07MUSD
$133.59MUSD
$126.10MUSD
$119.66MUSDP/E 18.6
$114.77MUSD
$83.73MUSDP/E 12.0
$94.75MUSD
$72.66MUSD
$67.25MUSD
$70.06MUSD
$62.42MUSDP/E 52.6
$63.44MUSDP/E 21.8
$60.48MUSD
$63.41MUSD
$53.86MUSD
$50.62MUSD
$49.37MUSD
$48.31MUSD
$42.20MUSD
$41.16MUSD
$33.86MUSDP/E Infinity
$31.75MUSD
$27.85MUSD
$26.87MUSD
$23.61MUSDP/E 204.0
$23.18MUSD
$22.62MUSD
$22.15MUSD
$18.56MUSD
$17.65MUSD
$14.93MUSD
$13.84MUSDP/E 16.8
$14.21MUSD
$11.64MUSD
$11.91MUSD
$9.88MUSD
$8.99MUSD
$8.21MUSD
$8.13MUSD
$6.05MUSDP/E 3.7
$6.17MUSD
$6.48MUSDP/E 0.3
$5.84MUSD
$5.46MUSDP/E Infinity
$3.29MUSDP/E 1.6
$2.01MUSD
$1.93MUSD
$2.08MUSDP/E 35.5
$1.54MUSD
$668.8KUSD
$173.7KUSDP/E 0.0
$175USD
Indicators:|
Key Statistics
Company
Market Cap355.90M $
Enterprise Value-12.71M $
Revenue (TTM)20.34M $
Gross Profit20.34M $
Net Income (TTM)-8.61M $
Revenue/Share3.235 USD
Last Price4.480 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees18
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS8112922005
Valuation
P/E (Trailing)—
P/E (Forward)-1.78
PEG—
EV/EBITDA—
EV/Revenue-0.62
P/S17.49
P/B0.84
EPS (TTM)-3.84
EPS (Forward)-2.52
52W Range
0.565077% of range5.620
52W High5.620 USD
52W Low0.5650 USD
Profitability
Gross Margin100.00%
Oper. Margin-119.95%
EBITDA Margin0.00%
Profit Margin-41.79%
ROE-17.44%
ROA-14.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.28M $
CapEx (TTM)—
FCF Margin11.85%
FCF Yield0.68%
Net Debt-57.20M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio3.94
Quick Ratio3.73
Book Value/Sh5.326 USD
Cash/Share5.968 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2020
Splits
Last Split1:8
Split DateJun 1, 2026
Analyst Consensus
Rating—
Target (Mean)33.55 USD
Upside (mean)+648.8%
Target Range24.00 USD – 44.64 USD
$24.00+648.8% to mean$44.64
# Analysts3
Ownership
Shares Out.79.44M
Float7.69M
Insiders2.00%
Institutions49.42%
Short Interest
Short Ratio4.9d
Short % Float3.91%
Short % Out.3.84%
Shares Short380.84K
Short (prev mo.)322.28K
Technical
SMA 505.091 (-12.0%)
SMA 2005.897 (-24.0%)
Beta1.10
S&P 52W Chg20.25%
Avg Vol (30d)79.78K
Avg Vol (10d)103.00K
Technical Indicators
RSI (14)59.0
MACD0.4147
MACD Signal0.4564
MACD Hist.-0.0417
BB Upper4.994 USD
BB Middle4.235 USD
BB Lower3.475 USD
BB Width35.86%
ATR (14)0.3549 USD
Vol Ratio (20d)0.36x